{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:15:43Z","timestamp":1788322543706,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.ejps.2016.05.008","type":"journal-article","created":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T23:02:27Z","timestamp":1462834947000},"page":"196-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"special_numbering":"C","title":["Non-invasive intranasal delivery of quetiapine fumarate loaded microemulsion for brain targeting: Formulation, physicochemical and pharmacokinetic consideration"],"prefix":"10.1016","volume":"91","author":[{"given":"Brijesh","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dignesh","family":"Khunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Padh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejps.2016.05.008_bb0005","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejps.2010.05.003","article-title":"Strategy for effective brain drug delivery","volume":"40","author":"Alam","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejps.2016.05.008_bb0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jsps.2010.02.005","article-title":"Influence of intestinal efflux pumps on the absorption and transport of furosemide","volume":"18","author":"Al-Mohizea","year":"2010","journal-title":"Saudi Pharm. J."},{"issue":"5","key":"10.1016\/j.ejps.2016.05.008_bb0015","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1773-2247(14)50093-7","article-title":"Effect of pharmaceutical excipients on the permeability of P-glycoprotein substrate","volume":"24","author":"Al-Mohizea","year":"2014","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ejps.2016.05.008_bb0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4137\/DTI.S12519","article-title":"P-glycoprotein inhibition for optimal drug delivery","volume":"7","author":"Amin","year":"2013","journal-title":"Drug Target Insights"},{"issue":"9","key":"10.1016\/j.ejps.2016.05.008_bb0025","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1023\/A:1018967116988","article-title":"Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2)","volume":"11","author":"Artursson","year":"1994","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.05.008_bb0030","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.carbpol.2013.08.027","article-title":"Chitosan and cyclodextrin in intranasal microemulsion for improved brain buspirone hydrochloride pharmacokinetics in rats","volume":"99","author":"Bshara","year":"2014","journal-title":"Carbohydr. Polym."},{"issue":"4","key":"10.1016\/j.ejps.2016.05.008_bb0035","first-page":"84","article-title":"LIPIDS\u2014Strategies to formulate lipid-based drug delivery systems","volume":"14","author":"Cannon","year":"2011","journal-title":"Am. Pharm. Rev."},{"issue":"1","key":"10.1016\/j.ejps.2016.05.008_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/S1984-82502010000100002","article-title":"Mucoadhesive drug delivery systems","volume":"46","author":"Carvalho","year":"2010","journal-title":"Braz. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejps.2016.05.008_bb0045","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00023210-200418030-00004","article-title":"Quetiapine","volume":"18","author":"Cheer","year":"2004","journal-title":"CNS drugs"},{"issue":"2","key":"10.1016\/j.ejps.2016.05.008_bb0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","article-title":"Modeling and comparison of dissolution profiles","volume":"13","author":"Costa","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.ejps.2016.05.008_bb0055","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.bbamem.2008.09.016","article-title":"Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery","volume":"1788","author":"Deli","year":"2009","journal-title":"Biochim. Biophys. Acta Biomembr."},{"issue":"4","key":"10.1016\/j.ejps.2016.05.008_bb0060","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2016.05.008_bb0065","series-title":"Guidance for Industry: Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products \u2014 Chemistry, Manufacturing, and Controls Documentation","first-page":"1","author":"FDA, US","year":"2002"},{"key":"10.1016\/j.ejps.2016.05.008_bb0070","series-title":"Draft Guidance for Industry: Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action","first-page":"1","author":"FDA, US","year":"2003"},{"issue":"4","key":"10.1016\/j.ejps.2016.05.008_bb0075","first-page":"1237","article-title":"Tissue distribution of the multidrug resistance protein","volume":"148","author":"Flens","year":"1996","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.ejps.2016.05.008_bb0080","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/jps.22307","article-title":"Intranasal clobazam delivery in the treatment of status epilepticus","volume":"100","author":"Florence","year":"2011","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejps.2016.05.008_bb0085","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2133\/dmpk.22.206","article-title":"Influence of formulation viscosity on drug absorption following nasal application in rats","volume":"22","author":"Furubayashi","year":"2007","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.ejps.2016.05.008_bb0090","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1358\/dot.1999.35.3.533849","article-title":"Quetiapine fumarate (Seroquel): a new atypical antipsychotic","volume":"35","author":"Goldstein","year":"1999","journal-title":"Drugs of today (Barcelona, Spain: 1998)"},{"issue":"8","key":"10.1016\/j.ejps.2016.05.008_bb0095","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1023\/A:1025053115583","article-title":"P-glycoprotein attenuates brain uptake of substrates after nasal instillation","volume":"20","author":"Graff","year":"2003","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.ejps.2016.05.008_bb0100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11095-004-9013-3","article-title":"Functional evidence for P-glycoprotein at the nose-brain barrier","volume":"22","author":"Graff","year":"2005","journal-title":"Pharm. Res."},{"issue":"9","key":"10.1016\/j.ejps.2016.05.008_bb0105","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/jps.20678","article-title":"The influence of actuation parameters on in vitro testing of nasal spray products","volume":"95","author":"Guo","year":"2006","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2016.05.008_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2013.10.011","article-title":"Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression","volume":"48","author":"Haque","year":"2014","journal-title":"J. Psychiatr. Res."},{"issue":"4","key":"10.1016\/j.ejps.2016.05.008_bb0115","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1517\/17425241003596337","article-title":"Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs","volume":"7","author":"He","year":"2010","journal-title":"Expert Opin. Drug Delivery"},{"issue":"2","key":"10.1016\/j.ejps.2016.05.008_bb0120","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jconrel.2005.10.002","article-title":"A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption","volume":"110","author":"Hong","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2016.05.008_bb0125","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1023\/A:1011929016601","article-title":"Chitosan and its use as a pharmaceutical excipient","volume":"15","author":"Illum","year":"1998","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.ejps.2016.05.008_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0928-0987(00)00087-7","article-title":"Transport of drugs from the nasal cavity to the central nervous system","volume":"11","author":"Illum","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2016.05.008_bb0135","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery\u2014possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.ejps.2016.05.008_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ddtec.2005.05.008","article-title":"Chitosan and the mucosal delivery of biotechnology drugs","volume":"2","author":"Issa","year":"2005","journal-title":"Drug Discov. Today: Technologies"},{"issue":"7","key":"10.1016\/j.ejps.2016.05.008_bb0145","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s11095-005-5420-3","article-title":"Localization and differential activity of P-glycoprotein in the bovine olfactory and nasal respiratory mucosae","volume":"22","author":"Kandimalla","year":"2005","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.ejps.2016.05.008_bb0150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0168-3659(02)00049-4","article-title":"Microemulsion formulation for enhanced absorption of poorly soluble drugs: I. Prescription design","volume":"81","author":"Kawakami","year":"2002","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.ejps.2016.05.008_bb0155","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1211\/jpp.61.05.0017","article-title":"Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats","volume":"61","author":"Khan","year":"2009","journal-title":"J. Pharm. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejps.2016.05.008_bb0160","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/02652048.2015.1010457","article-title":"Development and optimisation of mucoadhesive nanoparticles of acyclovir using design of experiments approach","volume":"32","author":"Kharia","year":"2015","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejps.2016.05.008_bb0165","first-page":"10","article-title":"Formulation and characterization of nasal sprays: an examination of nasal spray formulation parameters and excipients and their influence on key in vitro tests","author":"Kulkarni","year":"2012","journal-title":"Inhalation"},{"issue":"1","key":"10.1016\/j.ejps.2016.05.008_bb0170","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijpharm.2008.03.029","article-title":"Intranasal nanoemulsion based brain targeting drug delivery system of risperidone","volume":"358","author":"Kumar","year":"2008","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.ejps.2016.05.008_bb0175","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3109\/10717544.2014.920431","article-title":"Nasal-nanotechnology: revolution for efficient therapeutics delivery","volume":"23","author":"Kumar","year":"2016","journal-title":"Drug deliv."},{"key":"10.1016\/j.ejps.2016.05.008_bb0180","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.addr.2012.09.018","article-title":"Microemulsion-based media as novel drug delivery systems","volume":"64","author":"Lawrence","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2016.05.008_bb0185","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2147\/IJN.S61288","article-title":"Current approaches to enhance CNS delivery of drugs across the brain barriers","volume":"9","author":"Lu","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejps.2016.05.008_bb0190","first-page":"56","article-title":"Design and development of carbamazepine mucoadhesive microemulsion for intranasal delivery: an ex-vivo study","volume":"3","author":"Mandal","year":"2010","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"issue":"2","key":"10.1016\/j.ejps.2016.05.008_bb0195","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/10717544.2013.838713","article-title":"Insights into direct nose to brain delivery: current status and future perspective","volume":"21","author":"Mittal","year":"2014","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.ejps.2016.05.008_bb0200","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3109\/10717544.2014.907372","article-title":"Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route","volume":"23","author":"Mittal","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejps.2016.05.008_bb0205","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.ejps.2016.05.008_bb0210","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s12247-015-9232-7","article-title":"Formulation and development of in situ nasal gelling systems for quetiapine fumarate-loaded mucoadhesive microemulsion","volume":"10","author":"Patel","year":"2015","journal-title":"J. Pharm. Innov."},{"issue":"1","key":"10.1016\/j.ejps.2016.05.008_bb0215","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3109\/10717544.2014.912694","article-title":"Evaluation of brain targeting efficiency of intranasal microemulsion containing olanzapine: pharmacodynamic and pharmacokinetic consideration","volume":"23","author":"Patel","year":"2016","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.ejps.2016.05.008_bb0220","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijpharm.2010.05.041","article-title":"Preparation and evaluation of fexofenadine microemulsions for intranasal delivery","volume":"395","author":"Piao","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2016.05.008_bb0225","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0169-409X(96)00490-5","article-title":"Formulation of self emulsifying drug delivery systems","volume":"25","author":"Pouton","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.ejps.2016.05.008_bb0230","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejps.2012.10.029","article-title":"Ex vivo permeation characteristics of venlafaxine through sheep nasal mucosa","volume":"48","author":"Pund","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejps.2016.05.008_bb0235","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1067\/mcp.2000.109156","article-title":"Increased drug delivery to the brain by P-glycoprotein inhibition","volume":"68","author":"Sadeque","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2016.05.008_bb0240","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-409X(98)00085-4","article-title":"P-glycoprotein, a gatekeeper in the blood\u2013brain barrier","volume":"36","author":"Schinkel","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.ejps.2016.05.008_bb0245","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(02)00169-2","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview","volume":"55","author":"Schinkel","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2016.05.008_bb0250","author":"Schizophrenia, National Institute of Mental Health"},{"issue":"7","key":"10.1016\/j.ejps.2016.05.008_bb0255","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3109\/10717544.2013.878857","article-title":"Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization","volume":"22","author":"Shah","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejps.2016.05.008_bb0260","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejps.2015.07.002","article-title":"Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters","volume":"78","author":"Shah","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2016.05.008_bb0265","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3892\/etm.2015.2213","article-title":"Role of quetiapine beyond its clinical efficacy in bipolar disorder: from neuroprotection to the treatment of psychiatric disorders (review)","volume":"9","author":"Soeiro-de-Souza","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.ejps.2016.05.008_bb0270","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.colsurfb.2013.09.030","article-title":"Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment","volume":"113","author":"Sood","year":"2014","journal-title":"Colloids Surf., B"},{"key":"10.1016\/j.ejps.2016.05.008_bb0275","first-page":"15","article-title":"In vitro nasal spray characterization","author":"Suman","year":"2009","journal-title":"Inhalation"},{"issue":"5","key":"10.1016\/j.ejps.2016.05.008_bb0280","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3109\/09687688.2014.937468","article-title":"The blood-brain barrier: structure, function and therapeutic approaches to cross it","volume":"31","author":"Tajes","year":"2014","journal-title":"Mol. Membr. Biol."},{"issue":"2","key":"10.1016\/j.ejps.2016.05.008_bb0285","first-page":"195","article-title":"Analytical challenges and regulatory requirements for nasal drug products in Europe and the US","volume":"6","author":"Trows","year":"2014","journal-title":"Pharmatherapeutica"},{"issue":"3","key":"10.1016\/j.ejps.2016.05.008_bb0290","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/jps.20480","article-title":"Intranasal mucoadhesive microemulsions of clonazepam: preliminary studies on brain targeting","volume":"95","author":"Vyas","year":"2006","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejps.2016.05.008_bb0295","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-5173(99)00442-1","article-title":"Determination of baseline human nasal pH and the effect of intranasally administered buffers","volume":"198","author":"Washington","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2016.05.008_bb0300","unstructured":"World Health Organization (WHO). Schizophrenia. Fact sheet N 397. September 2014, Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs397\/en\/."},{"issue":"26","key":"10.1016\/j.ejps.2016.05.008_bb0305","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.1016\/j.biomaterials.2011.03.056","article-title":"Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening","volume":"32","author":"Yeh","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejps.2016.05.008_bb0310","series-title":"Surface Science Techniques","first-page":"3","article-title":"Contact angle and wetting properties","author":"Yuan","year":"2013"},{"issue":"3","key":"10.1016\/j.ejps.2016.05.008_bb0315","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejpb.2005.08.010","article-title":"Influence of cyclodextrins and chitosan, separately or in combination, on glyburide solubility and permeability","volume":"62","author":"Zerrouk","year":"2006","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809871630166X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809871630166X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T09:07:31Z","timestamp":1567847251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809871630166X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":63,"alternative-id":["S092809871630166X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2016.05.008","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-invasive intranasal delivery of quetiapine fumarate loaded microemulsion for brain targeting: Formulation, physicochemical and pharmacokinetic consideration","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2016.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}